WO2015157286A1 - Stable formulations for anti-cd19 antibodies and antibody-drug conjugates - Google Patents
Stable formulations for anti-cd19 antibodies and antibody-drug conjugates Download PDFInfo
- Publication number
- WO2015157286A1 WO2015157286A1 PCT/US2015/024719 US2015024719W WO2015157286A1 WO 2015157286 A1 WO2015157286 A1 WO 2015157286A1 US 2015024719 W US2015024719 W US 2015024719W WO 2015157286 A1 WO2015157286 A1 WO 2015157286A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody
- formulation
- stable
- stable formulation
- concentration
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 177
- 238000009472 formulation Methods 0.000 title claims abstract description 162
- 229940049595 antibody-drug conjugate Drugs 0.000 title abstract description 70
- 239000000611 antibody drug conjugate Substances 0.000 title abstract description 68
- 229930006000 Sucrose Natural products 0.000 claims description 39
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 39
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 39
- 229920000053 polysorbate 80 Polymers 0.000 claims description 39
- 229940068968 polysorbate 80 Drugs 0.000 claims description 39
- 239000005720 sucrose Substances 0.000 claims description 39
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 36
- 239000008363 phosphate buffer Substances 0.000 claims description 32
- MFRNYXJJRJQHNW-DEMKXPNLSA-N (2s)-2-[[(2r,3r)-3-methoxy-3-[(2s)-1-[(3r,4s,5s)-3-methoxy-5-methyl-4-[methyl-[(2s)-3-methyl-2-[[(2s)-3-methyl-2-(methylamino)butanoyl]amino]butanoyl]amino]heptanoyl]pyrrolidin-2-yl]-2-methylpropanoyl]amino]-3-phenylpropanoic acid Chemical group CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MFRNYXJJRJQHNW-DEMKXPNLSA-N 0.000 claims description 29
- 108010059074 monomethylauristatin F Proteins 0.000 claims description 29
- 239000007788 liquid Substances 0.000 claims description 27
- 239000002254 cytotoxic agent Substances 0.000 claims description 21
- 229940127089 cytotoxic agent Drugs 0.000 claims description 21
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 19
- 239000004094 surface-active agent Substances 0.000 claims description 15
- 235000000346 sugar Nutrition 0.000 claims description 14
- 108010044540 auristatin Proteins 0.000 claims description 12
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 8
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 8
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 8
- 239000004067 bulking agent Substances 0.000 claims description 8
- 239000008057 potassium phosphate buffer Substances 0.000 claims description 4
- 125000000185 sucrose group Chemical group 0.000 claims description 3
- 239000012064 sodium phosphate buffer Substances 0.000 claims description 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 abstract description 11
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 abstract description 11
- 108090000623 proteins and genes Proteins 0.000 description 46
- 235000018102 proteins Nutrition 0.000 description 41
- 102000004169 proteins and genes Human genes 0.000 description 41
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 32
- 230000000694 effects Effects 0.000 description 25
- 108060003951 Immunoglobulin Proteins 0.000 description 22
- 230000027455 binding Effects 0.000 description 22
- 102000018358 immunoglobulin Human genes 0.000 description 22
- 238000003860 storage Methods 0.000 description 22
- 239000003814 drug Substances 0.000 description 19
- 239000000427 antigen Substances 0.000 description 18
- 108091007433 antigens Proteins 0.000 description 18
- 102000036639 antigens Human genes 0.000 description 18
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 17
- 239000000872 buffer Substances 0.000 description 17
- 239000000546 pharmaceutical excipient Substances 0.000 description 17
- 108090000765 processed proteins & peptides Proteins 0.000 description 17
- 229940079593 drug Drugs 0.000 description 16
- 238000000034 method Methods 0.000 description 16
- 229910000160 potassium phosphate Inorganic materials 0.000 description 16
- 235000011009 potassium phosphates Nutrition 0.000 description 16
- BXTJCSYMGFJEID-XMTADJHZSA-N (2s)-2-[[(2r,3r)-3-[(2s)-1-[(3r,4s,5s)-4-[[(2s)-2-[[(2s)-2-[6-[3-[(2r)-2-amino-2-carboxyethyl]sulfanyl-2,5-dioxopyrrolidin-1-yl]hexanoyl-methylamino]-3-methylbutanoyl]amino]-3-methylbutanoyl]-methylamino]-3-methoxy-5-methylheptanoyl]pyrrolidin-2-yl]-3-met Chemical compound C([C@H](NC(=O)[C@H](C)[C@@H](OC)[C@@H]1CCCN1C(=O)C[C@H]([C@H]([C@@H](C)CC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)CCCCCN1C(C(SC[C@H](N)C(O)=O)CC1=O)=O)C(C)C)OC)C(O)=O)C1=CC=CC=C1 BXTJCSYMGFJEID-XMTADJHZSA-N 0.000 description 15
- ORFNVPGICPYLJV-YTVPMEHESA-N (2s)-2-[[(2r,3r)-3-[(2s)-1-[(3r,4s,5s)-4-[[(2s)-2-[[(2s)-2-[6-(2,5-dioxopyrrol-1-yl)hexanoyl-methylamino]-3-methylbutanoyl]amino]-3-methylbutanoyl]-methylamino]-3-methoxy-5-methylheptanoyl]pyrrolidin-2-yl]-3-methoxy-2-methylpropanoyl]amino]-3-phenylpropan Chemical compound C([C@H](NC(=O)[C@H](C)[C@@H](OC)[C@@H]1CCCN1C(=O)C[C@H]([C@H]([C@@H](C)CC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)CCCCCN1C(C=CC1=O)=O)C(C)C)OC)C(O)=O)C1=CC=CC=C1 ORFNVPGICPYLJV-YTVPMEHESA-N 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 13
- 102000004196 processed proteins & peptides Human genes 0.000 description 13
- 235000001014 amino acid Nutrition 0.000 description 12
- 229920001184 polypeptide Polymers 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 125000003275 alpha amino acid group Chemical group 0.000 description 11
- 229940024606 amino acid Drugs 0.000 description 11
- 150000001413 amino acids Chemical class 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 11
- 229940126534 drug product Drugs 0.000 description 11
- 239000012634 fragment Substances 0.000 description 11
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 11
- 239000000825 pharmaceutical preparation Substances 0.000 description 11
- 230000008859 change Effects 0.000 description 10
- 230000002378 acidificating effect Effects 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 239000008194 pharmaceutical composition Substances 0.000 description 9
- 150000003839 salts Chemical class 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 229910019142 PO4 Inorganic materials 0.000 description 8
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 8
- 239000010452 phosphate Substances 0.000 description 8
- 241000894007 species Species 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 239000002253 acid Substances 0.000 description 7
- -1 acidic species Substances 0.000 description 7
- 230000015556 catabolic process Effects 0.000 description 7
- 238000006731 degradation reaction Methods 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 229940127121 immunoconjugate Drugs 0.000 description 7
- 239000012669 liquid formulation Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 239000012906 subvisible particle Substances 0.000 description 7
- 150000008163 sugars Chemical class 0.000 description 7
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 6
- 229920001214 Polysorbate 60 Polymers 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 6
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 6
- 229940113124 polysorbate 60 Drugs 0.000 description 6
- 239000003381 stabilizer Substances 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 5
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 5
- 239000007857 degradation product Substances 0.000 description 5
- 238000004108 freeze drying Methods 0.000 description 5
- 230000007774 longterm Effects 0.000 description 5
- 230000009870 specific binding Effects 0.000 description 5
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 4
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 4
- 102000012745 Immunoglobulin Subunits Human genes 0.000 description 4
- 108010079585 Immunoglobulin Subunits Proteins 0.000 description 4
- 102000004243 Tubulin Human genes 0.000 description 4
- 108090000704 Tubulin Proteins 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 239000012931 lyophilized formulation Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000001542 size-exclusion chromatography Methods 0.000 description 4
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 3
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 3
- 102000029749 Microtubule Human genes 0.000 description 3
- 108091022875 Microtubule Proteins 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 239000006172 buffering agent Substances 0.000 description 3
- 239000006227 byproduct Substances 0.000 description 3
- 238000002144 chemical decomposition reaction Methods 0.000 description 3
- 230000001085 cytostatic effect Effects 0.000 description 3
- 230000006240 deamidation Effects 0.000 description 3
- 239000008380 degradant Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 229940072221 immunoglobulins Drugs 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 230000010534 mechanism of action Effects 0.000 description 3
- 210000004688 microtubule Anatomy 0.000 description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 2
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 2
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 239000008351 acetate buffer Substances 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 230000003139 buffering effect Effects 0.000 description 2
- 125000000837 carbohydrate group Chemical group 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000025084 cell cycle arrest Effects 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 239000000824 cytostatic agent Substances 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 210000003712 lysosome Anatomy 0.000 description 2
- 230000001868 lysosomic effect Effects 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 238000007539 photo-oxidation reaction Methods 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 229940068977 polysorbate 20 Drugs 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 239000008227 sterile water for injection Substances 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 239000008362 succinate buffer Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
- UPMLOUAZCHDJJD-UHFFFAOYSA-N 4,4'-Diphenylmethane Diisocyanate Chemical compound C1=CC(N=C=O)=CC=C1CC1=CC=C(N=C=O)C=C1 UPMLOUAZCHDJJD-UHFFFAOYSA-N 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- KWTQSFXGGICVPE-WCCKRBBISA-N Arginine hydrochloride Chemical compound Cl.OC(=O)[C@@H](N)CCCN=C(N)N KWTQSFXGGICVPE-WCCKRBBISA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000035404 Autolysis Diseases 0.000 description 1
- 208000004736 B-Cell Leukemia Diseases 0.000 description 1
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 241000212384 Bifora Species 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 1
- DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 230000004668 G2/M phase Effects 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101100383038 Homo sapiens CD19 gene Proteins 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 229920001612 Hydroxyethyl starch Polymers 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- AYRXSINWFIIFAE-SCLMCMATSA-N Isomaltose Natural products OC[C@H]1O[C@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)[C@@H](O)[C@@H](O)[C@@H]1O AYRXSINWFIIFAE-SCLMCMATSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- AYRXSINWFIIFAE-UHFFFAOYSA-N O6-alpha-D-Galactopyranosyl-D-galactose Natural products OCC1OC(OCC(O)C(O)C(O)C(O)C=O)C(O)C(O)C1O AYRXSINWFIIFAE-UHFFFAOYSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 229920002253 Tannate Polymers 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- 238000005411 Van der Waals force Methods 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000001408 amides Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940125644 antibody drug Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 238000005277 cation exchange chromatography Methods 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000015861 cell surface binding Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000000562 conjugate Substances 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 150000001945 cysteines Chemical class 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 125000002228 disulfide group Chemical group 0.000 description 1
- 150000002019 disulfides Chemical class 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000009513 drug distribution Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002121 endocytic effect Effects 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- DLRVVLDZNNYCBX-CQUJWQHSSA-N gentiobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-CQUJWQHSSA-N 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940097042 glucuronate Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- JEGUKCSWCFPDGT-UHFFFAOYSA-N h2o hydrate Chemical compound O.O JEGUKCSWCFPDGT-UHFFFAOYSA-N 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 150000002440 hydroxy compounds Chemical class 0.000 description 1
- 229940050526 hydroxyethylstarch Drugs 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000002998 immunogenetic effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 description 1
- TWBYWOBDOCUKOW-UHFFFAOYSA-M isonicotinate Chemical compound [O-]C(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-M 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000013627 low molecular weight specie Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- YVFMFWAUSKFVGO-UHFFFAOYSA-N naphthalene-2-carboperoxoic acid Chemical class C1=CC=CC2=CC(C(=O)OO)=CC=C21 YVFMFWAUSKFVGO-UHFFFAOYSA-N 0.000 description 1
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028043 self proteolysis Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000000859 sublimation Methods 0.000 description 1
- 230000008022 sublimation Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
- A61J1/06—Ampoules or carpules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
Definitions
- This disclosure provides optimized formulations for CD 19 antibodies and antibody- drug conjugates (ADCs).
- CD19 is a member of the immunoglobulin superfamily. See, e.g., Tedder & Isaacs, / Immunol, 143:712-717 (1989) and Del Nagro et al., Immunol Res, 31: 119-131 (2005). It is a B cell-specific marker not known to be expressed by any cell outside of the B lineage. CD 19 expression is maintained upon malignant transformation, thus, CD19 is found on malignant cells in the majority of patients with B-cell leukemia or non-Hodgkin lymphoma.
- SGN-CD19A is a CD19-directed antibody-drug conjugate (ADC) consisting of three components: 1) the humanized antibody hBU12, which specifically binds the human CD 19 protein, 2) the microtubule disrupting agent, monomethyl auristatin F (MMAF), and 3) a stable linker, maleimidocaproyl, that covalently attaches MMAF to hBU12.
- ADC CD19-directed antibody-drug conjugate
- This disclosure provides stable formulations of an anti-CD 19 antibody including a phosphate buffer.
- the anti-CD19 antibody has a light chain variable region of SEQ ID NO: l and a heavy chain variable region of SEQ ID NO:2, and the phosphate buffer has a pH value between 5.0 and 7.0.
- the phosphate buffer diminishes the occurance of oxidation of the antibody in the presence of light.
- the phosphate buffer is a sodium phosphate buffer.
- the phosphate buffer is a potassium phosphate buffer.
- the phosphate buffer has a pH between 5.5 and 6.5.
- the anti-CD 19 antibody formulation includes a phosphate buffer having a pH of about 6.0.
- the phosphate buffer of the formulation has a pH of 6.0.
- this disclosure provides an anti-CD 19 antibody with a light chain variable region of SEQ ID NO: l and a heavy chain variable region of SEQ ID NO:2 in a stable formulation that includes a phosphate buffer.
- the anti-CD 19 antibody is conjugated to a cytotoxic agent.
- the cytotoxic agent can be an auristatin and a preferred auristatin is monomethylauristatin F (MMAF).
- MMAF can be conjugated to the antibody via a maleimidocaproyl (mc) linker.
- this disclosure provides an anti-CD 19 antibody with a light chain variable region of SEQ ID NO: l and a heavy chain variable region of SEQ ID NO:2 in a stable formulation that includes a phosphate buffer and a surfactant.
- a preferred surfactant is polysorbate 80.
- the polysorbate 80 can be present at a concentration between 0.01 and 0.05% weight/volume. In one embodiment, the polysorbate 80 concentration is about 0.02%. In a preferred embodiment, the , the polysorbate 80 concentration is 0.02%.
- this disclosure provides an anti-CD 19 antibody with a light chain variable region of SEQ ID NO: l and a heavy chain variable region of SEQ ID NO:2 in a stable formulation that includes a phosphate buffer and a bulking agent, e.g., a sugar.
- a phosphate buffer e.g., a sugar.
- useful sugars include sucrose and trehalose.
- the sugar concentration is between 10 mg/ml and 75 mg/ml.
- the sugar is sucrose.
- the sucrose concentration is about 60 mg/ml.
- the sucrose concentration is 60 mg/ml.
- this disclosure provides an anti-CD 19 antibody with a light chain variable region of SEQ ID NO: l and a heavy chain variable region of SEQ ID NO:2 in a stable formulation that includes a potassium phosphate at about pH 6.0; about 0.02% polysorbate 80, and about 60 mg/ml sucrose.
- the anti-CD19 antibody is conjugated to a cytotoxic agent.
- a preferred cytotoxic agent is the drug-linker mcMMAF.
- the stable formulation of the anti-CD 19 antibody can be lyophilized before storage. A vial can be used for stage of the stable lyophilized the anti-CD 19 antibody formulation.
- the lyophilized the anti- CD ⁇ antibody formulation is then reconstituted in a sterile liquid before adminstration to a ptient.
- the lyophilized formulation is stable for up to eighteen months at 25°C.
- the stable formulation of the anti-CD 19 antibody is a liquid formulation and is stored in the liquid state.
- the liquid fomulation is stored in a vial in an amount appropriate for adminstration to a patient.
- formulation is stable for up to eighteen months at 5°C.
- this disclosure provides an anti-CD 19 antibody with a light chain variable region of SEQ ID NO: l and a heavy chain variable region of SEQ ID NO:2 in a stable formulation that includes a potassium phosphate at pH 6.0; 0.02% polysorbate 80, and 60 mg/ml sucrose.
- the anti-CD19 antibody is conjugated to a cytotoxic agent.
- a preferred cytotoxic agent is the drug-linker mcMMAF.
- the stable formulation of the anti-CD 19 antibody can be lyophilized before storage. A vial can be used for stage of the stable lyophilized the anti-CD 19 antibody formulation.
- the lyophilized the anti-CD 19 antibody formulation is then reconstituted in a sterile liquid before adminstration to a ptient. .
- the lyophilized formulation is stable for up to eighteen months at 25°C.
- the stable formulation of the anti-CD 19 antibody is a liquid formulation and is stored in the liquid state.
- the liquid fomulation is stored in a vial in an amount appropriate for adminstration to a patient.
- the liquid formulation is stable for up to eighteen months at 5°C.
- stable in the context of isolated antibody formulations or antibody-drug conjugate formulations as described herein, refers to a formulation in which the antibody or antibody-drug conjugate therein essentially retains its physical and chemical identity and integrity upon storage.
- Various analytical techniques for measuring protein stability are available in the art (see, e.g., Peptide and Protein Drug Delivery, 247-301 (Vincent Lee Ed., Marcel Dekker, Inc., New York, N.Y., Pubs. 1991) and Jones, Adv. Drug Delivery Rev. 10:29- 90, 1993).
- Exemplary techniques for measuring protein stability are also described herein (see Examples, infra). Stability can be measured at a selected temperature for a selected time period.
- the formulation may be kept at a higher or "accelerated" temperature, for example, 40°C for 1 week to 1 month or more at which time stability is measured.
- the formulation is refractory to the formation of by-products of the component antibody protein, for example, high molecular weight aggregation products, low molecular weight degradation or fragmentation products, acidic species, chemical degradants, or mixtures thereof.
- stability refers to the length of time over which a molecular species such as an antibody retains its original chemical identity, for example, primary, secondary, and/or tertiary structure.
- organic or inorganic salts of a compound can contain at least one amino group, and accordingly acid addition salts can be formed with the amino group.
- Exemplary salts include, but are not limited to, sulfate, trifluoroacetate, citrate, acetate, oxalate, chloride, bromide, iodide, nitrate, bisulfate, phosphate, acid phosphate, isonicotinate, lactate, salicylate, acid citrate, tartrate, oleate, tannate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucuronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, p toluenesulfonate, and pamoate (i.e., 1,1' methylene
- a pharmaceutically acceptable salt may involve the inclusion of another molecule such as an acetate ion, a succinate ion or other counterion.
- the counterion may be any organic or inorganic moiety that stabilizes the charge on the parent compound.
- a pharmaceutically acceptable salt may have more than one charged atom in its structure. Instances where multiple charged atoms are part of the pharmaceutically acceptable salt can have multiple counter ions. Hence, a pharmaceutically acceptable salt can have one or more charged atoms and/or one or more counterion.
- a "polypeptide” or “polypeptide chain” is a polymer of amino acid residues joined by peptide bonds, whether produced naturally or synthetically. Polypeptides of less than about 10 amino acid residues are commonly referred to as “peptides.”
- a "protein” is a macromolecule comprising one or more polypeptide chains.
- a protein may also comprise non-peptidic components, such as carbohydrate groups. Carbohydrates and other non-peptidic substituents may be added to a protein by the cell in which the protein is produced, and will vary with the type of cell. Proteins are defined herein in terms of their amino acid backbone structures; substituents such as carbohydrate groups are generally not specified, but may be present nonetheless.
- amino-terminal and “carboxyl-terminal” are used herein to denote positions within polypeptides. Where the context allows, these terms are used with reference to a particular sequence or portion of a polypeptide to denote proximity or relative position. For example, a certain sequence positioned carboxyl-terminal to a reference sequence within a polypeptide is located proximal to the carboxyl terminus of the reference sequence, but is not necessarily at the carboxyl terminus of the complete polypeptide.
- antibody is used herein to denote immunoglobulin proteins produced by the body in response to the presence of an antigen and that bind to the antigen, as well as antigen- binding fragments and engineered variants thereof.
- antibody includes, for example, intact monoclonal antibodies comprising full-lengh immunoglobulin heavy and light chains (e.g., antibodies produced using hybridoma technology) and antigen-binding antibody fragments, such as F(ab')2 and Fab fragments.
- antibody is used expansively to include any protein that comprises an antigen-binding site of an antibody and is capable of specifically binding to its antigen.
- the term "genetically engineered antibodies” means antibodies wherein the amino acid sequence has been varied from that of a native antibody. Because of the relevance of recombinant DNA techniques in the generation of antibodies, one need not be confined to the sequences of amino acids found in natural antibodies; antibodies can be redesigned to obtain desired characteristics. The possible variations are many and range from the changing of just one or a few amino acids to the complete redesign of, for example, the variable or constant region. Changes in the constant region will, in general, be made in order to improve or alter characteristics such as, e.g., complement fixation, interaction with cells, and other effector functions. Typically, changes in the variable region will be made in order to improve the antigen-binding characteristics, improve variable region stability, or reduce the risk of immunogenicity.
- An "antigen-binding site of an antibody” is that portion of an antibody that is sufficient to bind to its antigen.
- the minimum such region is typically a variable domain or a genetically engineered variant thereof.
- Single-domain binding sites can be generated from camelid antibodies (see Muyldermans and Lauwereys, J. Mol. Recog. 12: 131-140, 1999; Nguyen et al., EMBO J. 19:921-930, 2000) or from VH domains of other species to produce single-domain antibodies ("dAbs"; see Ward et al., Nature 341:544-546, 1989; US Patent No. 6,248,516 to Winter et al.).
- an antigen-binding site is a polypeptide region having only 2 complementarity determining regions (CDRs) of a naturally or non-naturally (e.g., mutagenized) occurring heavy chain variable domain or light chain variable domain, or combination thereof (see, e.g., Pessi et al., Nature 362:367-369, 1993; Qiu et al., Nature Biotechnol. 25:921-929, 2007). More commonly, an antigen-binding site of an antibody comprises both a heavy chain variable (VH) domain and a light chain variable (VL) domain that bind to a common epitope.
- VH heavy chain variable
- VL light chain variable
- an antibody may include one or more components in addition to an antigen-binding site, such as, for example, a second antigen-binding site of an antibody (which may bind to the same or a different epitope or to the same or a different antigen), a peptide linker, an immunoglobulin constant region, an immunoglobulin hinge, an amphipathic helix (see Pack and Pluckthun, Biochem.
- a non-peptide linker an oligonucleotide (see Chaudri et al., FEBS Letters 450:23-26, 1999), a cytostatic or cytotoxic drug, and the like, and may be a monomeric or multimeric protein.
- molecules comprising an antigen-binding site of an antibody include, for example, Fv, single-chain Fv (scFv), Fab, Fab', F(ab')2, F(ab)c, diabodies, dAbs, minibodies, nanobodies, Fab-scFv fusions, bispecific (scFv)4-IgG, and bispecific (scFv)2-Fab.
- scFv single-chain Fv
- Fab single-chain Fv
- dAbs minibodies
- nanobodies Fab-scFv fusions
- bispecific (scFv)4-IgG bispecific (scFv)2-Fab.
- immunoglobulin refers to a protein consisting of one or more polypeptides substantially encoded by immunoglobulin gene(s).
- immunoglobulin constitutes the basic structural unit of native (i.e., natural) antibodies in vertebrates. This form is a tetramer and consists of two identical pairs of immunoglobulin chains, each pair having one light chain and one heavy chain. In each pair, the light and heavy chain variable regions (VL and VH) are together primarily responsible for binding to an antigen, and the constant regions are primarily responsible for the antibody effector functions.
- VL and VH variable regions
- Five classes of immunoglobulin protein (IgG, IgA, IgM, IgD, and IgE) have been identified in higher vertebrates. IgG comprises the major class; it normally exists as the second most abundant protein found in plasma.
- IgG In humans, IgG consists of four subclasses, designated IgGl, IgG2, IgG3, and IgG4.
- the heavy chain constant regions of the IgG class are identified with the Greek symbol ⁇ .
- immunoglobulins of the IgGl subclass contain a ⁇ heavy chain constant region.
- Each immunoglobulin heavy chain possesses a constant region that consists of constant region protein domains (CHI, hinge, CH2, and CH3; IgG3 also contains a CH4 domain) that are essentially invariant for a given subclass in a species.
- DNA sequences encoding human and non-human immunoglobulin chains are known in the art.
- Full-length immunoglobulin "light chains" (about 25 Kd or 214 amino acids) are encoded by a variable region gene at the amino-terminus (encoding about 110 amino acids) and a by a kappa or lambda constant region gene at the carboxyl-terminus.
- immunoglobulin "heavy chains" (about 50 Kd or 446 amino acids) are encoded by a variable region gene (encoding about 116 amino acids) and a gamma, mu, alpha, delta, or epsilon constant region gene (encoding about 330 amino acids), the latter defining the antibody's isotype as IgG, IgM, IgA, IgD, or IgE, respectively.
- the variable and constant regions are joined by a "J" region of about 12 or more amino acids, with the heavy chain also including a "D” region of about 10 more amino acids.
- An immunoglobulin light or heavy chain variable region (also referred to herein as a "light chain variable domain” (“VL domain”) or “heavy chain variable domain” (“VH domain”), respectively) consists of a "framework” region interrupted by three hypervariable regions, also called “complementarity determining regions” or “CDRs.”
- the framework regions serve to align the CDRs for specific binding to an epitope of an antigen.
- the term “hypervariable region” or “CDR” refers to the amino acid residues of an antibody that are primarily responsible for antigen binding.
- both VL and VH domains comprise the following framework (FR) and CDR regions: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4.
- FR framework
- CDR regions FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4.
- the assignment of amino acids to each domain is in accordance with the definitions of Kabat, Sequences of Proteins of Immunological Interest (National Institutes of Health, Bethesda, MD, 1987 and 1991), or Chothia & Lesk, J. Mol. Biol. 196:901-917, 1987; Chothia et al., Nature 342:878-883, 1989.
- Kabat also provides a widely used numbering convention (Kabat numbering) in which corresponding residues between different heavy chains or between different light chains are assigned the same number.
- CDRs 1, 2, and 3 of a VL domain are also referred to herein, respectively, as CDR-Ll, CDR-L2, and CDR-L3;
- CDRs 1, 2, and 3 of a VH domain are also referred to herein, respectively, as CDR-Hl, CDR-H2, and CDR- H3.
- the term “monoclonal antibody” as used herein is not limited to antibodies produced through hybridoma technology.
- the term “monoclonal antibody” refers to an antibody that is derived from a single clone, including any eukaryotic, prokaryotic, or phage clone, and not the method by which it is produced.
- chimeric antibody refers to an antibody having variable domains derived from a first species and constant regions derived from a second species.
- immunoglobulins or antibodies can be constructed, for example by genetic engineering, from immunoglobulin gene segments belonging to different species.
- the term "humanized antibody,” as defined infra, is not intended to encompass chimeric antibodies.
- humanized antibodies are chimeric in their construction (i.e., comprise regions from more than one species of protein), they include additional features (i.e., variable regions comprising donor CDR residues and acceptor framework residues) not found in chimeric immunoglobulins or antibodies, as defined herein.
- humanized VH domain or “humanized VL domain” refers to an
- immunoglobulin VH or VL domain comprising some or all CDRs entirely or substantially from a non-human donor immunoglobulin (e.g., a mouse or rat) and variable region framework sequences entirely or substantially from human immunoglobulin sequences.
- the non-human immunoglobulin providing the CDRs is called the "donor” and the human immunoglobulin providing the framework is called the "acceptor.”
- humanized antibodies may retain non-human residues within the human variable domain framework regions to enhance proper binding characteristics (e.g., mutations in the frameworks may be required to preserve binding affinity when an antibody is humanized).
- a “humanized antibody” is an antibody comprising one or both of a humanized VH domain and a humanized VL domain. Immunoglobulin constant region(s) need not be present, but if they are, they are entirely or substantially from human immunoglobulin constant regions. [0028] A CDR in a humanized antibody is "substantially from” a corresponding CDR in a non- human antibody when at least 60%, at least 85%, at least 90%, at least 95% or 100% of corresponding residues (as defined by Kabat) are identical between the respective CDRs.
- the CDRs of the humanized VH or VL domain have no more than six (e.g., no more than five, no more than four, no more than three, no more than two, or nor more than one) amino acid substitutions across all three CDRs relative to the corresponding non- human VH or VL CDRs.
- variable region framework sequences of an antibody VH or VL domain or, if present, a sequence of an immunoglobulin constant region are "substantially from” a human VH or VL framework sequence or human constant region, respectively, when at least 85%, at least 90%, at least 95%, or 100% of corresponding residues defined by Kabat are identical.
- all parts of a humanized antibody, except possibly the CDRs are entirely or substantially from corresponding parts of natural human immunoglobulin sequences.
- Specific binding of an antibody to its target antigen means an affinity of at least 10 6 ,
- Specific binding is detectably higher in magnitude and distinguishable from non-specific binding occurring to at least one unrelated target.
- Specific binding can be the result of formation of bonds between particular functional groups or particular spatial fit (e.g., lock and key type) whereas nonspecific binding is usually the result of van der Waals forces.
- Specific binding does not, however, necessarily imply that a monoclonal antibody binds one and only one target.
- amino acid residues corresponding to those specified by SEQ ID NO includes post-translational modifications of such residues.
- anti-CD 19 antibody refers to an antibody that specifically binds to the human CD 19 protein.
- the anti-CD 19 antobidy comprises the CDRs of the light chain variable region of SEQ ID NO: 1 and the CDRs of the heavy chain variable region of SEQ ID NO:2.
- the anti-CD19 antobidy comprises the light chain variable region of SEQ ID NO: 1 and the heavy chain variable region of SEQ ID NO:2.
- the anti-CD19 antibody includes a human constant region and is an IgGl antibody.
- by-product includes undesired products, which detract or diminish the proportion of therapeutic antibody-drug conjugate in a given formulation.
- Typical by-products include aggregates of the antibody-drug conjugate, fragments of the antibody-drug conjugate (for example, produced by degradation of the antibody protein by deamidation or hydrolysis or chemical degradation and fragmentation of the drug-linker), acidic variants of the antibody-drug conjugate, or mixtures thereof.
- An antibody-drug conjugate is an antibody conjugated to a cytotoxic drug typically via a linker.
- the linker may comprise a cleavable unit or may be non-cleavable.
- Cleavable units include, for example, disulfide containing linkers that are cleavable through disulfide exchange, acid-labile linkers that are cleavable at acidic pH, and linkers that are cleavable by hydrolases, esterases, peptidases, and glucoronidases (e.g., peptide linkers and glucoronide linkers).
- Non-cleavable linkers are believed to release drug via a proteolytic antibody degradation mechanism.
- high molecular weight aggregates includes aggregates of the antibody-drug conjugate (ADC), as well as aggregates comprising fragments of the ADC (for example, produced by degradation of the polypeptide by, for example, hydrolysis) and aggregates comprising a mixtures of the ADC and such fragments.
- ADC antibody-drug conjugate
- fragments of the ADC for example, produced by degradation of the polypeptide by, for example, hydrolysis
- aggregates comprising a mixtures of the ADC and such fragments.
- SEC size-exclusion chromatography
- high molecular weight aggregates are complexes which have a molecular weight which is greater than the therapeutic monomer ADC.
- an ADC in which the antibody component is a tetramer consisting of two identical pairs of immunoglobulin chains, each pair having one light chain and one heavy chain (e.g., of the IgG isotype), such aggregates are greater than about 150 kD.
- the antibody component has a molecular weight greater than or less than that of a typical monospecific, tetrameric antibody protein consisting of two immunoglobulin light chains and two immunoglobulin heavy chains (e.g., single-chain antibodies or bispecific antibodies)
- the size of such aggregates can vary accordingly.
- low molecular weight degradation product includes, for example, fragments of the antibody-drug conjugate (ADC) such as, for example, fragments brought about by deamidation or hydrolysis.
- ADC antibody-drug conjugate
- SEC size-exclusion chromatography
- low molecular weight degradation products have a molecular weight that is less than the therapeutic monomer ADC.
- ADC antibody-drug conjugate
- such degradation products are less than about 150 kD.
- the size of such degradation products can vary accordingly.
- An "acidic variant" of an antibody-drug conjugate (ADC) of interest is an ADC variant that is more acidic than the experimental PI of the ADC.
- the presence of acid variants may be determined by, e.g., cation exchange chromatography or imaging capillary IEF (icIEF).
- An example of an acidic variant is a deamidated variant.
- Deamidated variants of a protein molecule are those in which one or more neutral amide side chain(s) have been converted to a residue with an overall acidic character (e.g., one or more asparagine residue(s) of the original polypeptide have been converted to aspartate).
- liquid refers to a solution suitable for altering or achieving an exemplary or appropriate concentration or concentrations as described herein.
- container refers to something into which an object or liquid can be placed or contained, e.g., for storage (for example, a holder, receptacle, vessel, or the like).
- administration route includes art-recognized administration routes for delivering a therapeutic protein such as, for example, parenterally, intravenously,
- intramuscularly, or subcutaneously For administration of an ADC for the treatment of cancer, administration into the systemic circulation by intravenous or subcutaneous administration may be desired.
- administration For treatment of a cancer characterized by a solid tumor, administration can be localized directly into the tumor, if so desired.
- treatment refers to the administration of a therapeutic agent to a patient, who has a disease with the purpose to cure, heal, alleviate, delay, relieve, alter, remedy, ameliorate, improve or affect the disease.
- patient includes human and other mammalian subjects that receive either prophylactic or therapeutic treatment.
- an effective amount refers to an amount that is sufficient to achieve or at least partially achieve the desired effect, e.g., sufficient to inhibit the occurrence or ameliorate one or more symptoms of a disease or disorder.
- An effective amount of a pharmaceutical composition is administered in an "effective regime.”
- the term “effective regime” refers to a combination of amount of the composition being administered and dosage frequency adequate to accomplish prophylactic or therapeutic treatment of the disease or disorder.
- dosage unit form refers to a physically discrete unit suitable as unitary dosages for a patient to be treated, each unit containing a predetermined quantity of active compound (an ADC in accordance with the present invention) calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier, diluent, or excipient.
- active compound an ADC in accordance with the present invention
- Actual dosage levels of an ADC in a formulation of the present invention may be varied so as to obtain an amount of the ADC that is effective to achieve a desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient.
- the selected dosage level will depend upon a variety of pharmacokinetic factors including the activity of the particular compositions of the present invention employed, the route of administration, the time of administration, the rate of excretion of the particular compound being employed, the duration of the treatment, other drugs, compounds and/or materials used in combination with the particular compositions employed, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and like factors well-known in the medical arts.
- a "cytotoxic effect” refers to the depletion, elimination and/or the killing of a target cell.
- a “cytotoxic agent” refers to an agent that has a cytotoxic effect on a cell.
- a “cytostatic effect” refers to the inhibition of cell proliferation.
- a “cytostatic agent” refers to an agent that has a cytostatic effect on a cell, thereby inhibiting the growth and/or expansion of a specific subset of cells.
- Two amino acid sequences have "100% amino acid sequence identity" if the amino acid residues of the two amino acid sequences are the same when aligned for maximal correspondence. Sequence comparisons can be performed using standard software programs such as those included in the LASERGENE bioinformatics computing suite, which is produced by DNASTAR (Madison, Wisconsin). Other methods for comparing two nucleotide or amino acid sequences by determining optimal alignment are well-known to those of skill in the art. (See, e.g., Peruski and Peruski, The Internet and the New Biology: Tools for Genomic and Molecular Research (ASM Press, Inc. 1997); Wu et al.
- Two amino acid sequences are considered to have "substantial sequence identity” if the two sequences have at least 80%, at least 85%, at least 90%, or at least 95% sequence identity relative to each other.
- Percentage sequence identities are determined with antibody sequences maximally aligned by the Kabat numbering convention. After alignment, if a subject antibody region (e.g., the entire variable domain of a heavy or light chain) is being compared with the same region of a reference antibody, the percentage sequence identity between the subject and reference antibody regions is the number of positions occupied by the same amino acid in both the subject and reference antibody region divided by the total number of aligned positions of the two regions, with gaps not counted, multiplied by 100 to convert to percentage.
- a subject antibody region e.g., the entire variable domain of a heavy or light chain
- compositions refers to a preparation which is in such form as to permit the biological activity of the active ingredient to be effective (when administered to a subject), and which contains no additional components which are unacceptably toxic to a subject to which the formulation would be administered. Such formulations are sterile.
- compositions or methods "comprising” one or more recited elements may include other elements not specifically recited.
- Reference to a numerical range herein e.g., "X to Y” or “from X to Y” includes the endpoints defining the range and all values falling within the range.
- the term “about” denotes an approximate range of plus or minus 10% from a specified value. For instance, the language “about 20%” encompasses a range of 18-22%. As used herein, about also includes the exact amount. Hence “about 20%” means “about 20%” and also “20%.”
- Figure 1A provides an assessment of the stability of the humanized anti-CD19 antibody, hBU12, in various buffers at various pH values.
- Figure IB provides an assessment of the stability of the humanized anti-CD 19 antibody hBU12 conjugated to MMAF, SGN-CD19A, in various buffers at various pH values.
- Figure 2 provides an assessment of the effect of pH on the chemical stability of the humanized anti-CD19 antibody hBU12 conjugated to MMAF, SGN-CD19A.
- Figure 3 A demonstrates the effect of freeze/thaw on sub visible particles in hBU12 formulation without polysorbate 80 (0 and 1 freeze/thaw cycle).
- Figure 3B demonstrates the effect of freeze/thaw on subvisible particles in hBU12 formulation without polysorbate 80 (2 and 3 freeze/thaw cycles).
- Figure 4 demonstrates the effect of freeze/thaw on subvisible particles in hBU12 formulation with 0.01% polysorbate 80 (0, 1, 2 and 3 freeze/thaw cycles).
- Figure 5 demonstrates the effect of freeze/thaw on subvisible particles in hBU12 formulation with 0.02% polysorbate 80 (0, 1, 2 and 3 freeze/thaw cycles).
- Figure 6 demonstrates the effect of freeze/thaw on subvisible particles in hBU12 formulation with 0.03% polysorbate 80 (0, 1, 2 and 3 freeze/thaw cycles).
- Figure 7 summarizes data on the effect of two sugars, sucrose and trehalose, on the stability of CD 19 ADC lyophilized formulations.
- Figure 8 provides the structure of SGN-CD19A, a CD 19 antibody drug conjugate (ADC) comprising the mcMMAF drug linker and the humanized antibody hBU12. DETAILED DESCRIPTION
- This invention provides stable formulations of anti-CD 19 antibodies and of ADC's comprising anti-CD 19 antibodies.
- the formulations include a phosphate buffer, a sugar, and polysorbate-80.
- the formulations provide stability for the anti-CD19 antibodies and ADC's comprising anti-CD 19 antibodies in both liquid and lyophilized embodiments.
- the invention provides a stable formulation of a humanized anti-CD19 antibody, hBU12, as described below. While working with the hBU12 antibody, it was discovered that the hBU12 antibody was unexpectedly unstable and oxidized in the presence of light. An oxidized impurity was detected after incubation of the antibody in the presence of light. Many formulations were tested for their ability to improve the stability of the antibody in the presence of light and to decrease the amount the oxidized impurity. However, the greatest decrease in the oxidized impurity came with use of phosphate buffer in the formulation. The decrease in oxidation associated with light was seen in formulations of unconjugated hBU12 antibody, as well as formulations of the hBU12 antibody conjugated to a cytotoxic agent, for example, mcMMAF.
- a cytotoxic agent for example, mcMMAF.
- hBU12 formulation that improve the stability of the antibody or antibody drug conjugate.
- the optimized aspects include, for example, buffer pH, addition of sugars, and addition of surfactants.
- Anti-CD19 antibodies Anti-CD19 antibodies, ADC's, and formulations
- the pharmaceutical formulations of the present invention comprise a humanized antibody, or an antibody-drug conjugate, that binds specifically to the human CD 19 protein.
- CD 19 means a human CD 19 protein or cluster of differentiation 19 protein.
- the amino acid sequence of human CD19 is known and is disclosed, e.g., at NCBI Reference Sequence: NP_001171569.1.
- the CD19 protein is a marker for B-cell deveopment and is expressed on B cells at many stages of B cell development.
- the formulations disclosed herein are stable formulations of the SGN-19A therapeutic agent.
- SGN-CD19A is produced by the conjugation of drug-linker intermediate maleimidocaproyl monomethyl auristatin F (mcMMAF) to the humanized antibody hBU12 ( Figure 8). The points of attachment are cysteines produced by reduction of inter-chain disulfides.
- SGN-CD19A has an average of four drugs per antibody molecule.
- hBU12 is an IgGl antibody and the variable regions are joined to human heavy and light constant regions.
- US Patent No. 7,968,687 also provides methods for the synthesis of mcMMAF and its conjugation to hBU12.
- SGN-CD19A is an antibody-drug conjugate (ADC) that delivers mcMMAF to CD19-positive cells.
- ADC antibody-drug conjugate
- mcMMAF is a tubulin-binding molecule.
- SGN-CD19A has a proposed multi-step mechanism of action initiated by binding to their target on the cell surface and subsequent internalization. After cell surface binding, internalization, and trafficking of SGN- CD19A through the endocytic pathway, proteolytic degradation of hBU12 in the lysosomes releases the cysteine adduct of the drug linker in the form of cys-mcMMAF, which then becomes available for tubulin binding.
- cys-mcMMAF and mcMMAF are used interchangeably herein. Binding of the released drug to tubulin disrupts the cellular microtubule network, leading to G2/M phase cell cycle arrest and subsequent onset of apoptosis in the targeted cell.
- the antibody component of SGN-CD19A can degrade in the presence of light.
- the formulations disclosed herein provide improved stability of SGN-CD19A. Moreover, the formulations disclosed herein allow choice of liquid or lyophilized formulations, depending on the needs of the user.
- Excipients are additives that either impart or enhance the stability and delivery of a drug product (e.g., an antibody or ADC). Regardless of the reason for their inclusion, excipients are an integral component of a formulation and therefore need to be safe and well tolerated by patients. For protein drugs, the choice of excipients is particularly important because they can affect both efficacy and immunogenicity of the drug. Hence, protein formulations need to be developed with appropriate selection of excipients that afford suitable stability, safety, and marketability.
- excipients are also employed to reduce viscosity of high concentration protein formulations in order to enable their delivery and enhance patient convenience.
- excipients can be classified on the basis of the mechanisms by which they stabilize proteins against various chemical and physical stresses. Some excipients are used to alleviate the effects of a specific stress or to regulate a particular susceptibility of a specific protein. Other excipients have more general effects on the physical and covalent stabilities of proteins.
- the excipients described herein are organized either by their chemical type or their functional role in formulations. Brief descriptions of the modes of stabilization are provided when discussing each excipient type.
- biopharmaceutical formulation of the invention is selected based on the desired osmolality (i.e., isotonic, hypotonic or hypertonic) of the final solution as well as the amounts and osmolality of other components to be included in the formulation.
- desired osmolality i.e., isotonic, hypotonic or hypertonic
- the stability of a pharmacologically active protein formulation is usually observed to be maximal in a narrow pH range. This pH range of optimal stability needs to be identified early during pre-formulation studies. Several approaches, such as accelerated stability studies and calorimetric screening studies, are useful in this endeavor. See, e.g., Remmele R. L. Jr., et al., Biochemistry, 38(16): 5241-7 (1999).
- buffering agents are almost always employed to control pH in the formulation.
- the hBU12 antibody exhibited improved photostability in the presence of phosphate buffers, as compared to other buffering agents.
- the optimal pH value for stability was investigated and found to range between pH values of 5.5 and 6.5. In preferred embodiments the pH value is about 6.0. In further embodiments, the pH value is 6.0.
- the phosphate buffering compound may be present in any amount suitable to maintain the pH of the formulation at a predetermined level.
- the pH buffering concentration is between 0.1 mM and 500 mM (1 M).
- the phosphate buffering agent is at least 0.1, 0.5, 0.7, 0.8 0.9, 1.0, 1.2, 1.5, 1.7, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 40, 50, 60, 70, 80, 90, 100, 200, or 500 mM.
- a stabilizer (or a combination of stabilizers) is added to prevent or reduce storage-induced aggregation and chemical degradation.
- a hazy or turbid solution upon reconstitution indicates that the protein has precipitated or at least aggregated.
- stabilizer means an excipient capable of preventing aggregation or physical degradation, including chemical degradation (for example, autolysis, deamidation, oxidation, etc.) in an aqueous state.
- Stabilizers contemplated include, but are not limited to, sucrose, trehalose, mannose, maltose, lactose, glucose, raffinose, cellobiose, gentiobiose, isomaltose, arabinose, glucosamine, fructose, mannitol, sorbitol, glycine, arginine HCL, poly-hydroxy compounds, including polysaccharides such as dextran, starch, hydroxyethyl starch, cyclodextrins, N-methyl pyrollidene, cellulose and hyaluronic acid, sodium chloride. See, e.g., Carpenter et al., Develop. Biol.
- the stabilizer is incorporated in a concentration of about 0.1, 0.5, 0.7, 0.8 0.9, 1.0, 1.2, 1.5, 1.7, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 30, 40, 50, 60, 70, 80, 90, 100, or 200 mg/ml.
- sucrose or trehalose are used as stabilizing agents.
- the formulations also include appropriate amounts of bulking and osmolarity regulating agents.
- Bulking agents include, for example and without limitation, mannitol, glycine, sucrose, polymers such as dextran, polyvinylpyrolidone, carboxymethylcellulose, lactose, sorbitol, trehalose, or xylitol.
- the bulking agent is sucrose.
- the bulking agent is incorporated in a concentration of about 0.1, 0.5, 0.7, 0.8 0.9, 1.0, 1.2, 1.5, 1.7, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 30, 40, 50, 60, 70, 80, 90, 100, or 200 mg/ml..
- Surfactants are commonly used in protein formulations to prevent surface-induced degradation.
- Surfactants are amphipathic molecules with the capability of out-competing proteins for interfacial positions. Hydrophobic portions of the surfactant molecules occupy interfacial positions (e.g., air/liquid), while hydrophilic portions of the molecules remain oriented towards the bulk solvent.
- a surface layer of surfactant molecules serve to prevent protein molecules from adsorbing at the interface. Thereby, surface-induced degradation is minimized.
- Surfactants contemplated herein include, without limitation, fatty acid esters of sorbitan polyethoxylates, i.e. polysorbate 20 and polysorbate 80. The two differ only in the length of the aliphatic chain that imparts hydrophobic character to the molecules, C-12 and C-18, respectively. Accordingly, polysorbate-80 is more surface- active and has a lower critical micellar
- the surfactant is incorporated in a concentration of about 0.01 to about 0.5 g/L.
- the surfactant concentration is 0.005, 0.01, 0.02, 0.03, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9 or 1.0 g/L (also referred to as % weight/volume).
- the preferred surfactant is polysorbate-80.
- the antibody and ADC formulations disclosed herein are suitable for both liquid and lyophilized formulations. That is, the antibody and ADC formulations, e.g., of SGN-CD19A, can be prepared in the disclosed concentrations and stored as a liquid formulation until administered to a patient. Alternatively, a liquid formulation can be prepared, e.g., of SGN- CD19A, in the disclosed concentrations then lyophilized and stored in state, until reconstituted and administered to a patient.
- the stable formulation comprises an anti-CD 19 antibody at a concentration of between 5 and 25 mg/ml.
- the anti-CD 19 antibody is included at between 10 and 20 mg/ml.
- the anti-CD19 antibody is included at a concentration between 12.5 and 17.5 mg/ml.
- the anti-CD19 antibody is included at a concentration between 14 and 16 mg/ml.
- the anti-CD19 antibody is included at a concentration of about 15 mg/ml.
- the anti-CD 19 antibody is included at a concentration of 15 mg/ml.
- the stable formulation comprises an anti-CD 19 antibody conjugated to a cytotoxic agent at a concentration of between 5 and 25 mg/ml.
- the anti-CD 19 antibody conjugated to a cytotoxic agent is included at between 10 and 20 mg/ml.
- the anti-CD 19 antibody conjugated to a cytotoxic agent is included at a concentration between 12.5 and 17.5 mg/ml.
- the anti-CD19 antibody conjugated to a cytotoxic agent is included at a concentration between 14 and 16 mg/ml.
- the anti-CD19 antibody conjugated to a cytotoxic agent is included at a concentration of about 15 mg/ml.
- the anti-CD19 antibody conjugated to a cytotoxic agent is included at a concentration of 15 mg/ml.
- the stable formulation comprises an anti-CD 19 antibody conjugated to an auristatin at a concentration of between 5 and 25 mg/ml.
- the anti-CD 19 antibody conjugated to an auristatin is included at between 10 and 20 mg/ml.
- the anti-CD 19 antibody conjugated to an auristatin is included at a concentration between 12.5 and 17.5 mg/ml.
- the anti-CD19 antibody conjugated to an auristatin is included at a concentration between 14 and 16 mg/ml.
- the anti-CD 19 antibody conjugated to an auristatin is included at a concentration of about 15 mg/ml.
- the anti-CD 19 antibody conjugated to an auristatin is included at a concentration of 15 mg/ml.
- the stable formulation comprises an anti-CD 19 antibody conjugated to MMAF at a concentration of between 5 and 25 mg/ml.
- the anti-CD 19 antibody conjugated to MMAF is included at between 10 and 20 mg/ml.
- the anti-CD 19 antibody conjugated to MMAF is included at a concentration between 12.5 and 17.5 mg/ml.
- the anti-CD19 antibody conjugated to MMAFis included at a concentration between 14 and 16 mg/ml.
- the anti- CD ⁇ antibody conjugated to MMAF is included at a concentration of about 15 mg/ml.
- the anti-CD 19 antibody conjugated to MMAF is included at a concentration of 15 mg/ml.
- the stable formulation comprises an anti-CD 19 antibody comprising a light chain variable region of SEQ ID NO: l and a heavy chain variable region of SEQ ID NO:2 that is conjugated to MMAF at a concentration of between 5 and 25 mg/ml.
- the anti-CD 19 antibody comprising a light chain variable region of SEQ ID NO: 1 and a heavy chain variable region of SEQ ID NO:2 that is conjugated to MMAF is included at between 10 and 20 mg/ml.
- the anti-CD19 antibody comprising a light chain variable region of SEQ ID NO: l and a heavy chain variable region of SEQ ID NO:2 that is conjugated to MMAF is included at a concentration between 12.5 and 17.5 mg/ml. In other embodiments, the anti-CD19 antibody comprising a light chain variable region of SEQ ID NO: l and a heavy chain variable region of SEQ ID NO:2 that is conjugated to MMAF is included at a concentration between 14 and 16 mg/ml.
- the anti- CD ⁇ antibody comprising a light chain variable region of SEQ ID NO: l and a heavy chain variable region of SEQ ID NO:2 that is conjugated to MMAF is included at a concentration of about 15 mg/ml.
- the anti-CD 19 antibody comprising a light chain variable region of SEQ ID NO: l and a heavy chain variable region of SEQ ID NO:2 that is conjugated to MMAF is included at a concentration of 15 mg/ml.
- the stable formulation comprises a phosphate buffer with a pH value between 5.0 and 7.0. In other embodiments, the stable formulation comprises a phosphate buffer with a pH value between 5.5 and 6.5. In other embodiments, the stable formulation comprises a phosphate buffer with a pH value between 5.8 and 6.2. In other embodiments, the stable formulation comprises a phosphate buffer with a pH value between 5.9 and 6.1. In other embodiments, the stable formulation comprises a phosphate buffer with a pH value of about 6.0. In other embodiments, the stable formulation comprises a phosphate buffer with a pH value of 6.0
- the stable formulation comprises between 0.0% and 1% (W/V) polysorbate 80. In other embodiments, the stable formulation comprises between 0.05% and 0.5% (W/V) polysorbate 80. In other embodiments, the stable formulation comprises between 0.1% and 0.3% (W/V) polysorbate 80. In other embodiments, the stable formulation comprises about 0.2% (W/V) polysorbate 80. In other embodiments, the stable formulation comprises 0.2% (W/V) polysorbate 80.
- the stable formulation comprises between 20 and 100 mg/ml sucrose. In other embodiments, the stable formulation comprises between 30 and 90 mg/ml sucrose. In other embodiments, the stable formulation comprises between 40 and 80 mg/ml sucrose. In other embodiments, the stable formulation comprises between 50 and 70 mg/ml sucrose. In other embodiments, the stable formulation comprises between 55 and 65 mg/ml sucrose. In other embodiments, the stable formulation comprises about 60 mg/ml sucrose. In other embodiments, the stable formulation comprises 60 mg/ml sucrose.
- the stable formulation comprises an anti-CD 19 antibody at a concentration of about 15 mg/ml in 10 mM potassium phosphate, at a pH of about 6.0, with about 0.02% w/v polysorbate 80, and about 60 mg/ml sucrose.
- the stable formulation comprises an anti-CD 19 antibody at a concentration of 15 mg/ml in 10 mM potassium phosphate, at pH 6.0, with 0.02% w/v polysorbate 80, and 60 mg/ml sucrose.
- the stable formulation comprises an anti-CD 19 antibody conjugated to a cytotoxic agent at a concentration of about 15 mg/ml in 10 mM potassium phosphate, at a pH of about 6.0, with about 0.02% w/v polysorbate 80, and about 60 mg/ml sucrose.
- the stable formulation comprises an anti-CD 19 antibody conjugated to a cytotoxic agent at a concentration of 15 mg/ml in 10 mM potassium phosphate, at pH 6.0, with 0.02% w/v polysorbate 80, and 60 mg/ml sucrose.
- the stable formulation comprises an anti-CD 19 antibody conjugated to an auristatin at a concentration of about 15 mg/ml in 10 mM potassium phosphate, at a pH of about 6.0, with about 0.02% w/v polysorbate 80, and about 60 mg/ml sucrose.
- the stable formulation comprises an anti-CD 19 antibody conjugated to an auristatin at a concentration of 15 mg/ml in 10 mM potassium phosphate, at pH 6.0, with 0.02% w/v polysorbate 80, and 60 mg/ml sucrose.
- the stable formulation comprises an anti-CD 19 antibody conjugated to mcMMAF at a concentration of about 15 mg/ml in 10 mM potassium phosphate, at a pH of about 6.0, with about 0.02% w/v polysorbate 80, and about 60 mg/ml sucrose.
- the stable formulation comprises an anti-CD 19 antibody conjugated to mcMMAF at a concentration of 15 mg/ml in 10 mM potassium phosphate, at pH 6.0, with 0.02% w/v polysorbate 80, and 60 mg/ml sucrose.
- the stable formulation comprises comprises an anti-CD 19 antibody comprising a light chain variable region of SEQ ID NO: l and a heavy chain variable region of SEQ ID NO:2 that is conjugated to mcMMAF at a concentration of about 15 mg/ml in 10 mM potassium phosphate, at a pH of about 6.0, with about 0.02% w/v polysorbate 80, and about 60 mg/ml sucrose.
- the stable formulation comprises comprises an anti-CD 19 antibody comprising a light chain variable region of SEQ ID NO: l and a heavy chain variable region of SEQ ID NO:2 that is conjugated to mcMMAF at a concentration of 15 mg/ml in 10 mM potassium phosphate, at pH 6.0, with 0.02% w/v polysorbate 80, and 60 mg/ml sucrose.
- the stable formulation of a CD 19 antibody or ADC can be prepared as either a liquid or a lyophilized preparation. As disclosed herein, both the liquid and lyophilized versions of the formulation are stable over time. Once a liquid formulation is made it can then be stored before. Preferably storage of the liquid version will occur at or about 4°C.
- lyophilization is carried out using techniques common in the art. See, e.g., Tang et al., Pharm Res. 21: 191-200, (2004) and Chang et al, Pharm Res. 13:243-9 (1996).
- a lyophilization cycle is, in one aspect, composed of three steps: freezing, primary drying, and secondary drying. See, e.g., A. P. Mackenzie, Phil Trans R Soc London, Ser B, Biol 278: 167 (1977).
- the freezing step the solution is cooled to initiate ice formation. Furthermore, this step induces the crystallization of the bulking agent.
- the standard reconstitution practice for lyophilized material is to add back a volume of pure water or sterile water for injection (WFI) (typically equivalent to the volume removed during lyophilization), although dilute solutions of antibacterial agents are sometimes used in the production of pharmaceuticals for parenteral administration.
- WFI sterile water for injection
- the lyophilized material may be reconstituted as an aqueous solution.
- aqueous carriers e.g., sterile water for injection, or water with appropriate amounts of surfactants (for example, an aqueous suspension that contains the active compound in admixture with excipients suitable for the manufacture of aqueous suspensions).
- the stable CD 19 ADC formulations disclosed herein are administered to patients in need of treatment, e.g., patients with cancer that express extracellular CD19, e.g., non-hodgkin lymphoma or acute lymphoblastic leukemia or patients with an autoimmune disease that responds to treatment with a CD19 ADC.
- the CD19 formulations either liquid or reconstituted lyophilized formulations, are administered intravenously.
- compositions are carried out with the dose levels and pattern being selected by the treating physician.
- the appropriate dosage depends on the type of disease to be treated, as defined above, the severity and course of the disease, whether drug is administered for preventive or therapeutic purposes, previous therapy, the patient's clinical history and response to the drug, and the discretion of the attending physician.
- kits which comprise one or more liquid or lyophilized compositions packaged in a manner which facilitates their use for administration to subjects.
- a kit includes a stable pharmaceutical formulation described herein (e.g., a composition comprising a CD19 ADC, such as SGN-CD19A), packaged in a container such as a sealed bottle or vessel, with a label affixed to the container or included in the package that describes use of the compound or composition in practicing the method.
- the pharmaceutical formulation is packaged in the container such that the amount of headspace in the container (e.g., the amount of air between the liquid formulation and the top of the container) is very small.
- the amount of headspace is negligible (i.e., almost none).
- the kit contains a first container having a lyophilized stable CD 19 ADC formulation, such as SGN-CD19A, and a second container having a physiologically acceptable reconstitution solution for the composition.
- the pharmaceutical formulation is packaged in a unit dosage form.
- the kit may further include a device suitable for administering the pharmaceutical formulation according to a specific route of administration.
- the kit contains a label that describes use of the pharmaceutical formulations.
- Antibody hBU12 was observed to be unstable in the presence of light. Formulation studies indicated that buffer composition could influence the extent of photo-oxidation in hBU12. The following buffers were tested under intense light for their effect on the photo- stability of hBU12: 10 mM Na phosphate pH 6.5; 10 mM citrate, pH 6.5; and 10 mM histidine, pH 6.5. Each formulation had an hBU12 concentration of ⁇ 7 mg/mL. The samples were held in a photochamber and exposed to intense light over a period of twenty-four hours. Photo oxidation of hBU12 resulted increase in the oxidized Fab. The data in Table 1 shows change in oxidized Fab for each formulation over time and light exposure. The data indicates that the sodium phosphate formulation showed superior stability compared to citrate and histidine buffers.
- Table 1 Effect of buffer on antibody photo stability in intense light.
- hBU12 10 mM histidine, pH 6.0; 10 mM potassium phosphate, pH 6.0; 10 mM acetate, pH 6.0; and 10 mM succinate, pH 6.0.
- concentration of hBU12 was approximately 4 mg/mL in each formulation.
- Results are shown in Tables 2 and 3.
- hBU12 antibody formulated in a phosphate buffer at pH 6.0 was more photostable than the same antibody formulated in histidine, acetate or succinate buffers. See, e.g., Table 2.
- Table 3 provides the results in ambient light.
- hBU12 antibody formulated in a phosphate buffer at pH 6.0 was more photostable than the same antibody formulated in histidine, acetate or succinate buffers.
- Table 3 Effect of buffer on antibody photo stability in ambient light.
- the hBU12 antibody was conjugated to the auristatin monomethylauristatin F (MMAF) using a maleimidocproyl (mc) linker.
- MMAF auristatin monomethylauristatin F
- mc maleimidocproyl
- Phosphate buffer also stabilized the hBU12 ADC in the presence of light.
- the evaluation was done with phosphate and histidine buffers, at pH values ranging from 5.0 to 7.0.
- Formulations were prepared in lOmM histidine buffers at pH 5.0 (H5), pH 6.0 (H6), and pH 7.0 (H7), and lOmM potassium phosphate buffers at pH 6.0 (P6) and pH 7.0 (P7)
- the photostability of the CD19-ADC comprising hBU12 and MMAF was measured at zero and seven days of ambient light exposure. As before, the photo stability was assessed by measuring the amount of oxidized Fab or ADC produced under various conditions
- Figure IB shows that the CD 19 ADC comprising hBU12 and MMAF was most photostable in phosphate buffer at pH 6.0 (P6).
- Figure 2 shows that some degradants grew faster at high pH while others grew faster at low pH.
- the CD19 ADC comprising hBU12 and MMAF was most stable at pH 6.0.
- Tables 5 and 6 demonstrate the effects of sucrose on aggregate and fragment formation in the lyophilized formulation of a CD 19 ADC comprising hBU12 and MMAF over a two week period under stressed conditions, i.e., at 54°C. Lowest levels of aggregates and fragments (greatest stability) were seen after two weeks in the presence of 60mg/ml (6% w/v) sucrose. Table 5: Effect of sucrose on lyophilization stability - measurement of aggregates
- a formulated solution of CD19A ADC at 15 mg/mL in 10 mM phosphate, 6% w/v sucrose, 0.02% w/v polysorbate 80 was selected for further development.
- the stability of this formulation has been examined in both the liquid and lyophilized state.
- the formulated solution is filled directly into vials and stored as a liquid for long-term storage.
- the formulated solution is filled into vials and lyophilized to produce a solid product for long-term storage.
- the long-term stability of the liquid drug product is excellent as shown in Table 7.
- Most product quality attributes of the liquid drug product do not change significantly following 18 or 36 months of storage at 5°C.
- the biological assays and drug distribution on the ADC do not change.
- Attributes that do change slightly are high molecular weight (HMW) species, low molecular weight (LMW) species and acidic variants (AV).
- HMW high molecular weight
- LMW low molecular weight
- AV acidic variants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2942150A CA2942150A1 (en) | 2014-04-07 | 2015-04-07 | Stable formulations for anti-cd19 antibodies and antibody-drug conjugates |
SG11201607306PA SG11201607306PA (en) | 2014-04-07 | 2015-04-07 | Stable formulations for anti-cd19 antibodies and antibody-drug conjugates |
US15/301,049 US20170028062A1 (en) | 2014-04-07 | 2015-04-07 | Stable formulations for anti-cd19 antibodies and antibody-drug conjugates |
MX2016012259A MX2016012259A (en) | 2014-04-07 | 2015-04-07 | Stable formulations for anti-cd19 antibodies and antibody-drug conjugates. |
KR1020167027118A KR20160141726A (en) | 2014-04-07 | 2015-04-07 | Stable formulations for anti-cd19 antibodies and antibody-drug conjugates |
JP2016560486A JP2017512814A (en) | 2014-04-07 | 2015-04-07 | Stable formulations for anti-CD19 antibodies and antibody-drug conjugates |
AU2015243993A AU2015243993A1 (en) | 2014-04-07 | 2015-04-07 | Stable formulations for anti-CD19 antibodies and antibody-drug conjugates |
EA201692002A EA201692002A1 (en) | 2014-04-07 | 2015-04-07 | STABLE COMPOSITIONS FOR ANTIBODIES TO CD19 AND CONJUGATES ANTIBODECASTIC MEDICINE |
EP15776984.5A EP3129047B1 (en) | 2014-04-07 | 2015-04-07 | Stable formulations for anti-cd19 antibodies and antibody-drug conjugates |
CN201580017717.XA CN106132434A (en) | 2014-04-07 | 2015-04-07 | Anti-CD 19 antibodies and the stabilization formulations of antibody drug conjugates |
IL247700A IL247700A0 (en) | 2014-04-07 | 2016-09-08 | Stable formulations for anti-cd19 antibodies and antibody-drug conjugates |
US16/397,331 US20190381172A1 (en) | 2014-04-07 | 2019-04-29 | Stable formulations for anti-cd19 antibodies and antibody-drug conjugates |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461976313P | 2014-04-07 | 2014-04-07 | |
US61/976,313 | 2014-04-07 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/301,049 A-371-Of-International US20170028062A1 (en) | 2014-04-07 | 2015-04-07 | Stable formulations for anti-cd19 antibodies and antibody-drug conjugates |
US16/397,331 Continuation US20190381172A1 (en) | 2014-04-07 | 2019-04-29 | Stable formulations for anti-cd19 antibodies and antibody-drug conjugates |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015157286A1 true WO2015157286A1 (en) | 2015-10-15 |
Family
ID=54288329
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2015/024719 WO2015157286A1 (en) | 2014-04-07 | 2015-04-07 | Stable formulations for anti-cd19 antibodies and antibody-drug conjugates |
Country Status (12)
Country | Link |
---|---|
US (2) | US20170028062A1 (en) |
EP (1) | EP3129047B1 (en) |
JP (1) | JP2017512814A (en) |
KR (1) | KR20160141726A (en) |
CN (1) | CN106132434A (en) |
AU (1) | AU2015243993A1 (en) |
CA (1) | CA2942150A1 (en) |
EA (1) | EA201692002A1 (en) |
IL (1) | IL247700A0 (en) |
MX (1) | MX2016012259A (en) |
SG (1) | SG11201607306PA (en) |
WO (1) | WO2015157286A1 (en) |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018002031A1 (en) * | 2016-06-27 | 2018-01-04 | Morphosys Ag | Anti-cd19 antibody formulations |
WO2018075692A2 (en) | 2016-10-19 | 2018-04-26 | Invenra Inc. | Antibody constructs |
WO2019039483A1 (en) | 2017-08-23 | 2019-02-28 | 第一三共株式会社 | Antibody-drug conjugate preparation and lyophilization for same |
WO2019119822A1 (en) * | 2017-12-23 | 2019-06-27 | Uwell Biopharma Inc. | Pharmaceutical chimeric receptor composition and method thereof |
WO2019234136A1 (en) | 2018-06-05 | 2019-12-12 | King's College London | Btnl3/8 targeting constructs for delivery of payloads to the gastrointestinal system |
US11174318B2 (en) | 2016-12-22 | 2021-11-16 | Università Degli Studi Magna Graecia Catanzaro | Monoclonal antibody targeting a unique sialoglycosylated cancer-associated epitope of CD43 |
WO2022074206A1 (en) | 2020-10-08 | 2022-04-14 | Affimed Gmbh | Trispecific binders |
US11351257B2 (en) | 2016-07-15 | 2022-06-07 | Philogen S.P.A. | Antibody compositions |
EP3865154A4 (en) * | 2018-10-10 | 2022-11-09 | Astellas Pharma Inc. | Pharmaceutical composition containing tagged site-antihuman antibody fab fragment complex |
WO2023007023A1 (en) | 2021-07-30 | 2023-02-02 | Affimed Gmbh | Duplexbodies |
WO2023078968A1 (en) | 2021-11-03 | 2023-05-11 | Affimed Gmbh | Bispecific cd16a binders |
US11667724B2 (en) | 2017-07-07 | 2023-06-06 | Astellas Pharma Inc. | Anti-human CEACAM5 antibody Fab fragment |
US11679166B2 (en) | 2016-11-18 | 2023-06-20 | Astellas Pharma Inc. | Anti-human MUC1 antibody Fab fragment |
RU2800924C2 (en) * | 2018-10-10 | 2023-08-01 | Астеллас Фарма Инк. | Pharmaceutical composition containing complex marking site - fab-fragment of anti-human antibody |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3802617A4 (en) * | 2018-06-07 | 2022-04-27 | Cullinan Oncology, Inc. | Multi-specific binding proteins and methods of use thereof |
KR20200025629A (en) | 2018-08-31 | 2020-03-10 | 주식회사 두두원 | Multifunctional oral care device that combines LED light source for tooth whitening and automatic toothbrush |
BR112021015034A2 (en) | 2019-02-18 | 2021-10-05 | Eli Lilly And Company | THERAPEUTIC ANTIBODY FORMULATION |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6252055B1 (en) * | 1996-05-24 | 2001-06-26 | Glaxo Wellcome Inc. | Concentrated antibody preparation |
US20120148576A1 (en) * | 2009-03-06 | 2012-06-14 | Medlmmune, Llc | Humanized anti-cd 19 antibody formulations |
US20130209496A1 (en) * | 2010-10-22 | 2013-08-15 | Seatle Genetics, Inc. | Synergistic Effects Between Auristatin-Based Antibody Drug Conjugates And Inhibitors Of The PI3K-AKT mTOR Pathway |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2702555A1 (en) * | 2007-10-19 | 2009-04-23 | Seattle Genetics, Inc. | Cd19 binding agents and uses thereof |
JP5937966B2 (en) * | 2009-08-11 | 2016-06-22 | エージェンシー フォー サイエンス, テクノロジー アンド リサーチ | Particulate hyaluronic acid formulation for cellular delivery of bioactive substances |
-
2015
- 2015-04-07 KR KR1020167027118A patent/KR20160141726A/en unknown
- 2015-04-07 JP JP2016560486A patent/JP2017512814A/en active Pending
- 2015-04-07 AU AU2015243993A patent/AU2015243993A1/en not_active Abandoned
- 2015-04-07 CN CN201580017717.XA patent/CN106132434A/en active Pending
- 2015-04-07 EP EP15776984.5A patent/EP3129047B1/en active Active
- 2015-04-07 CA CA2942150A patent/CA2942150A1/en not_active Abandoned
- 2015-04-07 MX MX2016012259A patent/MX2016012259A/en unknown
- 2015-04-07 US US15/301,049 patent/US20170028062A1/en not_active Abandoned
- 2015-04-07 SG SG11201607306PA patent/SG11201607306PA/en unknown
- 2015-04-07 WO PCT/US2015/024719 patent/WO2015157286A1/en active Application Filing
- 2015-04-07 EA EA201692002A patent/EA201692002A1/en unknown
-
2016
- 2016-09-08 IL IL247700A patent/IL247700A0/en unknown
-
2019
- 2019-04-29 US US16/397,331 patent/US20190381172A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6252055B1 (en) * | 1996-05-24 | 2001-06-26 | Glaxo Wellcome Inc. | Concentrated antibody preparation |
US20120148576A1 (en) * | 2009-03-06 | 2012-06-14 | Medlmmune, Llc | Humanized anti-cd 19 antibody formulations |
US20130209496A1 (en) * | 2010-10-22 | 2013-08-15 | Seatle Genetics, Inc. | Synergistic Effects Between Auristatin-Based Antibody Drug Conjugates And Inhibitors Of The PI3K-AKT mTOR Pathway |
Non-Patent Citations (1)
Title |
---|
See also references of EP3129047A4 * |
Cited By (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018002031A1 (en) * | 2016-06-27 | 2018-01-04 | Morphosys Ag | Anti-cd19 antibody formulations |
KR102533875B1 (en) * | 2016-06-27 | 2023-05-18 | 모르포시스 아게 | Anti-CD19 Antibody Formulations |
JP2022119854A (en) * | 2016-06-27 | 2022-08-17 | モルフォシス・アーゲー | Anti-CD19 antibody formulation |
CN109415440A (en) * | 2016-06-27 | 2019-03-01 | 莫佛塞斯公司 | Anti- CD19 antibody preparation |
KR20190021373A (en) * | 2016-06-27 | 2019-03-05 | 모르포시스 아게 | Anti-CD19 antibody preparation |
EP3909985A1 (en) * | 2016-06-27 | 2021-11-17 | MorphoSys AG | Anti-cd19 antibody formulations |
JP2019524671A (en) * | 2016-06-27 | 2019-09-05 | モルフォシス・アーゲー | Anti-CD19 antibody preparation |
CN109415440B (en) * | 2016-06-27 | 2022-12-06 | 莫佛塞斯公司 | anti-CD19 antibody formulations |
IL263764B1 (en) * | 2016-06-27 | 2024-05-01 | Morphosys Ag | Anti-cd19 antibody formulations |
RU2748024C2 (en) * | 2016-06-27 | 2021-05-19 | МорфоСис АГ | Formulations based on cd19 antibody |
US11352423B2 (en) | 2016-06-27 | 2022-06-07 | Morphosys Ag | Anti-CD19 antibody formulations |
US11351257B2 (en) | 2016-07-15 | 2022-06-07 | Philogen S.P.A. | Antibody compositions |
WO2018075692A2 (en) | 2016-10-19 | 2018-04-26 | Invenra Inc. | Antibody constructs |
US11679166B2 (en) | 2016-11-18 | 2023-06-20 | Astellas Pharma Inc. | Anti-human MUC1 antibody Fab fragment |
US11965033B2 (en) | 2016-12-22 | 2024-04-23 | Università Degli Studi Magna Graecia Catanzaro | Monoclonal antibody targeting a unique sialoglycosylated cancer-associated epitope of CD43 |
US11174318B2 (en) | 2016-12-22 | 2021-11-16 | Università Degli Studi Magna Graecia Catanzaro | Monoclonal antibody targeting a unique sialoglycosylated cancer-associated epitope of CD43 |
US11667724B2 (en) | 2017-07-07 | 2023-06-06 | Astellas Pharma Inc. | Anti-human CEACAM5 antibody Fab fragment |
KR20200044044A (en) | 2017-08-23 | 2020-04-28 | 다이이찌 산쿄 가부시키가이샤 | Antibody-drug conjugate preparation and freeze-drying method thereof |
WO2019039483A1 (en) | 2017-08-23 | 2019-02-28 | 第一三共株式会社 | Antibody-drug conjugate preparation and lyophilization for same |
WO2019119822A1 (en) * | 2017-12-23 | 2019-06-27 | Uwell Biopharma Inc. | Pharmaceutical chimeric receptor composition and method thereof |
US11672827B2 (en) | 2017-12-23 | 2023-06-13 | Uwell Biopharma Inc. | Pharmaceutical chimeric receptor composition and method thereof |
WO2019234136A1 (en) | 2018-06-05 | 2019-12-12 | King's College London | Btnl3/8 targeting constructs for delivery of payloads to the gastrointestinal system |
EP3865154A4 (en) * | 2018-10-10 | 2022-11-09 | Astellas Pharma Inc. | Pharmaceutical composition containing tagged site-antihuman antibody fab fragment complex |
RU2800924C2 (en) * | 2018-10-10 | 2023-08-01 | Астеллас Фарма Инк. | Pharmaceutical composition containing complex marking site - fab-fragment of anti-human antibody |
WO2022074206A1 (en) | 2020-10-08 | 2022-04-14 | Affimed Gmbh | Trispecific binders |
WO2023007023A1 (en) | 2021-07-30 | 2023-02-02 | Affimed Gmbh | Duplexbodies |
WO2023078968A1 (en) | 2021-11-03 | 2023-05-11 | Affimed Gmbh | Bispecific cd16a binders |
Also Published As
Publication number | Publication date |
---|---|
KR20160141726A (en) | 2016-12-09 |
IL247700A0 (en) | 2016-11-30 |
EP3129047A4 (en) | 2017-05-10 |
EP3129047A1 (en) | 2017-02-15 |
CN106132434A (en) | 2016-11-16 |
JP2017512814A (en) | 2017-05-25 |
CA2942150A1 (en) | 2015-10-15 |
MX2016012259A (en) | 2017-01-06 |
SG11201607306PA (en) | 2016-09-29 |
US20170028062A1 (en) | 2017-02-02 |
US20190381172A1 (en) | 2019-12-19 |
EA201692002A1 (en) | 2017-01-30 |
AU2015243993A1 (en) | 2016-09-15 |
EP3129047B1 (en) | 2020-10-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20190381172A1 (en) | Stable formulations for anti-cd19 antibodies and antibody-drug conjugates | |
JP7162695B2 (en) | Antibody-drug conjugate lyophilized formulation | |
KR101923371B1 (en) | FORMULATION FOR ANTI-α4β7 ANTIBODY | |
AU2014248640B2 (en) | Cyclodextrin and antibody-drug conjugate formulations | |
MX2014013434A (en) | Lyophilised and aqueous anti-cd40 antibody formulations. | |
JP2008528638A5 (en) | ||
EP3207061A1 (en) | Anti-il-7r antibody compositions | |
WO2013190047A1 (en) | Pharmaceutical formulation | |
US20190134215A1 (en) | Combination of cd33 antibody drug conjugates with chemotherapeutic agents | |
KR20180069906A (en) | Anti-Factor D antibody preparation | |
KR20230167968A (en) | Viscosity reducing excipient composition and low-viscosity highly concentrated protein formulation comprising same | |
EA034583B1 (en) | USES OF ANTI-α4β7 ANTIBODY | |
NZ617833B2 (en) | Formulation for anti-?4?7 antibody |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15776984 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2942150 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 247700 Country of ref document: IL |
|
ENP | Entry into the national phase |
Ref document number: 2015243993 Country of ref document: AU Date of ref document: 20150407 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2016/012259 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 20167027118 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2016560486 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15301049 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2015776984 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2015776984 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 201692002 Country of ref document: EA |